该研究以Oncolytic virus VG161 in refractory hepatocellular carcinoma 为题，于 2025 年 3 月 19 日发表于 Nature 期刊，论文通讯作者为浙江大学医学院附属第一医院梁 ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management ...

Candel Therapeutics essentially uses a dual-virus strategy with CAN-2409 and CAN-3110 immunotherapies. Find out why CADL ...

A study appearing in Nature investigated the role of astrocytes, an abundant cell type in the brain, in regulating an immune ...

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

Oncolytic viral therapy offers new avenues in anticancer treatment, and two herpes simplex virus (HSV)-1-based virotherapies have recently gained approval for the treatment of advanced melanoma and ...

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

Amielle Moreno earned her doctorate in neuroscience from Emory University and has dedicated her career to science communication, news coverage, and medical writing and editing. She is a published ...

WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

This article focuses on one of those potential combination therapies: oncolytic viruses (OVs). In the tug-of-war between fire (immune stimulation) and ice (immune suppression), ice usually wins ...